A5010896931- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- Radiopharmaceutical Chemistry and Applications
- CRISPR and Genetic Engineering
- Peptidase Inhibition and Analysis
- Nanoplatforms for cancer theranostics
- Virus-based gene therapy research
- vaccines and immunoinformatics approaches
- Immune Cell Function and Interaction
Technical University of Munich
2018-2024
Klinikum rechts der Isar
2018-2022
Blocking the interaction of immune checkpoint molecule programmed cell death protein-1 and its ligand, PD-L1, using specific antibodies has been a major breakthrough for oncology. Whole-body PD-L1 expression PET imaging may potentially allow better prediction response to protein-1–targeted therapies. Imaging is feasible by with adnectin protein <sup>18</sup>F-BMS-986192. However, radiofluorination proteins such as BMS-986192 remains complex labeling yields are low. The goal this study was...
Cancer immunotherapy has proven high efficacy in treating diverse cancer entities by immune checkpoint modulation and adoptive T-cell transfer.However, patterns of treatment response differ substantially from conventional therapies, reliable surrogate markers are missing for early detection responders versus non-responders.Current imaging techniques using 18 F-fluorodeoxyglucose-positron-emmission-tomograpy ( F-FDG-PET) cannot discriminate, at times, between tumor progression...
Adoptive transfer of TCR transgenic T cells holds great promise for treating various cancers. So far, mainly semi-randomly integrating vectors have been used to genetically modify cells. These carry the risk insertional mutagenesis, and sole addition an exogenous potentially results in mispairing chains with endogenous ones. Established approaches using nonviral vectors, such as transposons, already reduce mutagenesis but not accomplished site-specific integration. Here, we CRISPR-Cas9 RNPs...
Neoantigens derived from somatic mutations correlate with therapeutic responses mediated by treatment immune checkpoint inhibitors. are therefore highly attractive targets for the development of approaches in personalized medicine, although many aspects their quality and associated not yet well understood. In a case study metastatic malignant melanoma, we aimed to perform an in-depth characterization neoantigens respective T-cell context modulation. Three neoantigens, which identified either...
Abstract Neoantigen-specific T cell receptors (neoTCRs) promise safe, personalized anti-tumor immunotherapy. However, detailed assessment of neoTCR-characteristics affecting therapeutic efficacy is mostly missing. Previously, we identified diverse neoTCRs restricted to different neoantigens in a melanoma patient. In this work, now combine single-cell TCR-sequencing and RNA-sequencing after neoantigen-specific restimulation peripheral blood-derived CD8 + cells We detect with specificity for...
Abstract Neoantigens derived from somatic mutations have been demonstrated to correlate with therapeutic responses mediated by treatment immune checkpoint inhibitors. are therefore highly attractive targets for the development of personalized medicine approaches although their quality and associated is not yet well understood. In a case study metastatic malignant melanoma, we performed an in-depth characterization neoantigens respective T-cell in context immunotherapy Ipilimumab. Three...
Abstract Neoantigen-specific T cell receptors (neoTCRs) promise a safe, highly personalized therapeutic approach in anti-tumor immunotherapy. Substantial progress has been made regarding their identification whereas detailed functional assessment of single TCR characteristics impacting efficacy is lacking. We previously identified and functionally characterized neoTCRs specific for neoepitopes derived from KIF2C SYTL4 demonstrating differences avidity patient with metastatic melanoma. In...
Ziel/Aim Tumor cells exploit checkpoint pathways by expressing coinhibitory proteins, like PD-L1 to evade antitumor immune response. As recently demonstrated in first patients, F-18-BMS-986192 (F-18-Adnectin) provides a promising means for vivo imaging and quantification of expression tumors. The high tumor uptake ligands suggests that may also be used as theranostic target. step applications radiolabeled we evaluated biodistribution Ga-68-Adnectin analogue.